AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. Oncotelic is a clinical-stage biopharmaceutical company advancing RNA-based, immunotherapy, and targeted therapeutics for cancer and underserv ...